Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    518 result(s) found for: pancreatic cancer. Displaying page 9 of 26.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2008-000814-65 Sponsor Protocol Number: PACT-12 Start Date*: 2008-02-26
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: Maintenance therapy with Sunitinib in pancreatic adenocarcinoma metastatic: Phase II randomized trial.
    Medical condition: Pancreatic adenocarcinoma metastatic
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004262-34 Sponsor Protocol Number: GRASPANC2013-03 Start Date*: 2014-02-24
    Sponsor Name:ERYTECH Pharma
    Full Title: Phase II, randomized, controlled, clinical trial exploring efficacy and safety of ERY001 (L-asparaginase encapsulated in Red Blood Cells) in association with gemcitabine or FOLFOX4 in second-line t...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004101-75 Sponsor Protocol Number: S56122-ML10190 Start Date*: 2014-03-28
    Sponsor Name:UZ Leuven
    Full Title: Randomized crossover trial to assess the effects and quality of life in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel: Q...
    Medical condition: locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005471-17 Sponsor Protocol Number: RASH Start Date*: 2012-05-08
    Sponsor Name:Klinikum der Universität München-Großhadern
    Full Title: Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors
    Medical condition: metastatic pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000590-21 Sponsor Protocol Number: FFC33-24 Start Date*: 2005-08-24
    Sponsor Name:Faustus Forschung Compagnie, Translational Cancer Research GmbH
    Full Title: A Phase II Study of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea (HECNU) in pancreatic cancer
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002386-30 Sponsor Protocol Number: 33-04 Start Date*: 2015-02-20
    Sponsor Name:Verein für Krebsforschung
    Full Title: Efficacy and Safety of Mistletoe Extract in the Palliative Therapy of Patients Suffering from Pancreatic Cancer (PALM-Pan)
    Medical condition: Locally advanced or metastatic adenocarcinoma of the pancreas (UICC stadium III or IV)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002071-34 Sponsor Protocol Number: ALLOCATE Start Date*: 2019-10-31
    Sponsor Name:Vejle Hospital
    Full Title: Allocation of patients with pre-treated solid tumors to anti-cancer therapy based on gene expression drug response prediction - a phase II basket trial
    Medical condition: Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    20.1 100000004864 10080083 Advanced lung cancer LLT
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    20.0 100000004864 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004449-28 Sponsor Protocol Number: PRODIGE37 Start Date*: 2015-02-05
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: A randomized multicenter phase II trial of a sequential chemotherapy of nab-paclitaxel + gemcitabine followed by FOLFIRI.3 versus nab-paclitaxel + gemcitabine in first line of pancreatic adenocarci...
    Medical condition: pancreas adenocarcinoma metastatic
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005873-25 Sponsor Protocol Number: SN201 Start Date*: 2022-04-28
    Sponsor Name:SOTIO Biotech a.s.
    Full Title: A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma
    Medical condition: Gastric and pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002844-10 Sponsor Protocol Number: CA209-032 Start Date*: 2013-11-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
    Medical condition: Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovari...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Ongoing) FI (Completed) IT (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000216-29 Sponsor Protocol Number: NL68762.078.19 Start Date*: 2019-08-07
    Sponsor Name:Erasmus MC
    Full Title: Safety and efficacy of the addition of IMM-101 Heat-Killed Whole Cell Mycobacterium obuense to standard stereotactic radiotherapy in locally advanced pancreatic cancer patients (LAPC-2 trial).
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003715-28 Sponsor Protocol Number: HALO-109-201 Start Date*: 2011-12-08
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003601-25 Sponsor Protocol Number: LipoGem-PII-1L-Pancr Start Date*: 2012-04-18
    Sponsor Name:Regulon AE
    Full Title: Randomised, Multicenter Phase III Clinical Study of Lipoplatin plus Gemcitabine Versus Gemcitabine as First-Line Treatment in Inoperable, Locally Advanced or Metastatic Pancreatic Cancer
    Medical condition: Patients with Inoperable, Locally Advanced or Metastatic Pancreatic Cancer, not previously treated with chemotherapy for the current disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2022-001867-29 Sponsor Protocol Number: 1081HV Start Date*: 2022-11-02
    Sponsor Name:Amsterdam UMC
    Full Title: [68Ga]Ga-FAPI-46 positron emission tomography in pancreaticobiliary cancers: a pharmacokinetics, repeatability and diagnostic accuracy study.
    Medical condition: Pancreatic carcinoma and cholangiocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002936-27 Sponsor Protocol Number: IOR 157 01 Start Date*: 2007-12-03
    Sponsor Name:ISTITUTO ONCOLOGICO ROMAGNOLO
    Full Title: A Phase II Dose-Finding Study of weekly pemetrexed in combination with Radiotherapy in locally advanced pancreatic adenocarcinoma
    Medical condition: locally advanced adenocarcinoma of the exocrine pancreas not amenable to surgical resection.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052747 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002264-41 Sponsor Protocol Number: IMGC936-0901 Start Date*: 2022-02-21
    Sponsor Name:ImmunoGen, Inc.
    Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-003751-37 Sponsor Protocol Number: BO21128 Start Date*: 2008-05-29
    Sponsor Name:F. Hoffmann-La Roche
    Full Title: A Phase II, Dose-Escalation to rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer.
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed) AT (Completed) DE (Completed) GB (Completed) LT (Completed) GR (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2018-002852-34 Sponsor Protocol Number: S61508 Start Date*: 2020-02-10
    Sponsor Name:UZLeuven
    Full Title: Progression-free Survival after Minimally Invasive Surgical Microwave Ablation plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer. MIMIPA...
    Medical condition: Unresectable Locally Advanced Non Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004429-26 Sponsor Protocol Number: Atu027-I-02 Start Date*: 2013-02-25
    Sponsor Name:Silence Therapeutics GmbH
    Full Title: A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma
    Medical condition: Locally advanced or metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    17.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004243-21 Sponsor Protocol Number: M200-1205 Start Date*: 2005-03-15
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: Phase 2 Open-Label Study of Volociximab (M200) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer Not Previously Treated with Chemotherapy
    Medical condition: metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 28 19:24:21 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA